Discuss strategies for the management of patients with lipid disorders.
|
|
|
|
|
|
Recognize the prevalence of triglyceride-rich remnant lipoproteins in ASCVD.
|
|
|
|
|
|
Discuss treatment options for hypertriglyceridemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD.
|
|
|
|
|
|
Outline appropriate therapy options for high CVD risk patients with elevated triglyceride levels.
|
|
|
|
|
|
Identify the clinical and genetic attributes, available diagnostic tools, and screening practices to aid the identification of individuals with chylomicronemia syndrome.
|
|
|
|
|
|
Explain the role of genetic testing in the identification of familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia (MCM).
|
|
|
|
|
|
Outline appropriate therapy options for patients with chylomicronemia syndrome and multifactorial chylomicronemia.
|
|
|
|
|
|
Discuss strategies to improve the knowledge, skills, or performance of the healthcare team.
|
|
|
|
|
|